Strategy increased its Bitcoin holdings by purchasing 811 BTC for about $65.5 million, bringing its total to 849,327 BTC at an average price of $75,451 per coin. The company raised $164 million by selling shares of its common stock, using part of the proceeds to buy Bitcoin and the rest to boost its cash reserves. Additionally, Strategy repurchased preferred stock worth $208.2 million and paid $43.4 million in preferred dividends. As of November 1, it held $4.79 billion in USD reserves and $132.7 million in cash, signaling strong liquidity alongside its large Bitcoin position.
Strategy's Bitcoin holdings reached 849,327 BTC after adding about $65.5 million worth of 811 BTC. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 02, 2026 20:43 WIB: out of 50 major cryptocurrencies, 8 rose and 41 fell. Notable movers include SXP down 46.27% to Rp37, BAL up 11.14% to Rp16,297, and EOS up 8.13% to Rp12,649.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
